- Previous Close
2.3900 - Open
2.2900 - Bid 2.0800 x 100
- Ask 2.2400 x 100
- Day's Range
2.0700 - 2.2900 - 52 Week Range
1.6000 - 5.8850 - Volume
180,126 - Avg. Volume
243,990 - Market Cap (intraday)
81.413M - Beta (5Y Monthly) -0.40
- PE Ratio (TTM)
-- - EPS (TTM)
-0.9500 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
18.00
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer. The company is also developing V2ACT Immunotherapy for treating pancreatic cancer. Genelux Corporation has a licensing agreement with ELIAS Animal Health, LLC for V-VET1, a clinical stage animal health product candidate. The company was incorporated in 2001 and is headquartered in Westlake Village, California.
www.genelux.comRecent News: GNLX
View MorePerformance Overview: GNLX
Trailing total returns as of 4/7/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: GNLX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: GNLX
View MoreValuation Measures
Market Cap
89.87M
Enterprise Value
60.85M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
9.40k
Price/Book (mrq)
3.42
Enterprise Value/Revenue
7.61k
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-63.28%
Return on Equity (ttm)
-130.58%
Revenue (ttm)
8k
Net Income Avi to Common (ttm)
-29.87M
Diluted EPS (ttm)
-0.9500
Balance Sheet and Cash Flow
Total Cash (mrq)
30.89M
Total Debt/Equity (mrq)
7.11%
Levered Free Cash Flow (ttm)
-10.14M